Updates from The Motley Fool

Latest updates on Emergent BioSolutions from Fool.com.

Stock Charting

EBS vs. SPY | 2 Year Performance
EBS 1-Day Stock Chart
EBS 5-Day Stock Chart
EBS 1-Month Stock Chart
EBS 3-Month Stock Chart
EBS 6-Month Stock Chart
EBS 1-Year Stock Chart
EBS 2-Year Stock Chart
EBS 5-Year Stock Chart
View Interactive EBS Charts
Sponsored by

Key Data Points

Primary metrics and data points about Emergent BioSolutions.
Current Price: $39.20
Prev Close: $39.64
Open: $39.54
Bid: $37.60
Ask: $45.00
Day's Range: $38.81 - $40.08
52wk Range: $27.68 - $40.96
Volume: 266,375
Avg Vol 430,491
Market Cap: $1.53B
P/E (ttm): 28.11
EPS (ttm): $1.41
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Emergent BioSolutions.
CAPS Rating 4 out of 5
481 Outperform
17 Underperform
CAPS All Stars
89 Outperform
6 Underperform

How do you think Emergent BioSolutions will perform against the market?

You pick for Emergent BioSolutions is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS

CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Daniel J. Abdun-Nabi, CEO

60% Approve

Based on 50 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Emergent BioSolutions.

Emergent BioSolutions makes the only FDA-approved anthrax vaccine.

  • Exchange: NYSE
  • Sector: Healthcare
  • Industry: Drug Makers